Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus - PubMed (original) (raw)

Review

Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus

Xin Li et al. Biomol Ther (Seoul). 2020.

Abstract

Hypersecretion of pulmonary mucus is a major pathophysiological feature in allergic and inflammatory respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Overproduction and/or oversecretion of mucus cause the airway obstruction and the colonization of pathogenic microbes. Developing a novel pharmacological agent to regulate the production and/or secretion of pulmonary mucus can be a useful strategy for the effective management of pathologic hypersecretion of mucus observed in COPD and asthma. Thus, in the present review, we tried to give an overview of the conventional pharmacotherapy for mucus-hypersecretory diseases and recent research results on searching for the novel candidate agents for controlling of pulmonary mucus hypersecretion, aiming to shed light on the potential efficacious pharmacotherapy of mucus-hypersecretory diseases.

Keywords: Hypersecretion; Mucin; Mucus; Pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have declared that there is no conflict of interest.

Figures

Fig. 1

Fig. 1

The strategy for the effective management of pathologic hypersecretion of mucus observed in COPD and asthma. Hypersecretion of pulmonary mucus is a major pathophysiological feature in allergic and inflammatory respiratory diseases including asthma and COPD. Overproduction and/or oversecretion of mucus provoke the airway obstruction and the colonization of pathogenic microbes. Developing a novel pharmacological agent to regulate the production and/or secretion of pulmonary mucus can be a useful strategy for the effective management of pathologic hypersecretion of mucus observed in COPD and asthma.

Similar articles

Cited by

References

    1. Advenier C., Lagente V., Boichot E. The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Eur. Respir. J. 1997;10:1892–1906. doi: 10.1183/09031936.97.10081892. - DOI - PubMed
    1. Aggarwal S., Kim S. W., Cheon K., Tabassam F. H., Yoon J. H., Koo J. S. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell. 2006;17:566–575. doi: 10.1091/mbc.e05-06-0519. - DOI - PMC - PubMed
    1. Albers G. M., Tomkiewicz R. P., May M. K., Ramirez O. E., Rubin B. K. Ring distraction technique for measuring surface tension of sputum: relationship to sputum clearability. J. Appl. Physiol. 1996;81:2690–2695. doi: 10.1152/jappl.1996.81.6.2690. - DOI - PubMed
    1. Allegra L., Bossi R., Braga P. C. Action of sobrerol on mucociliary transport. Respiration. 1981;42:105–109. doi: 10.1159/000194412. - DOI - PubMed
    1. Barnes P. J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 1998;94:557–572. doi: 10.1042/cs0940557. - DOI - PubMed

Publication types

LinkOut - more resources